Press Releases

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Sep 26, 2002
NeoTherapeutics Regains Compliance with NASDAQ Minimum Bid Requirement Thursday September 26, 11:54 am ET IRVINE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOTD) announced today that NASDAQ has notified the Company that it has regained compliance with NASDAQ's
Sep 05, 2002
NeoTherapeutics' Stockholders Approve Reverse Stock Split and Proposal for New Financings Trading on post-split basis to commence September 6, 2002 Thursday September 5, 2:41 pm ET IRVINE, Calif., Sept. 5 /PRNewswire-FirstCall/-- NeoTherapeutics Inc. (Nasdaq: NEOT), announced today that its
Aug 22, 2002
NeoTherapeutics Announces Organizational Changes Designed to Bring On-Going Monthly Expenses Below $500,000 Changes solidify strategic commitment to anti-cancer drug development and out-licensing of neurology products IRVINE, Calif., Aug. 22 /PRNewswire-FirstCall/-- NeoTherapeutics, Inc.
Aug 21, 2002
NeoTherapeutics Announces New Financial Leadership IRVINE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT ) announced today the retirement of Samuel Gulko, Senior Vice President, Finance; Chief Financial Officer; Secretary; and, Treasurer. Mr.
Aug 20, 2002
NeoTherapeutics Announces Major Strategic Restructuring Company to focus resources on development of phase 3 anti-cancer drug and licensing out anti-psychotic and attention deficit drugs IRVINE, Calif., Aug. 20 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc.
Aug 16, 2002
NeoTherapeutics Names Dr. Rajesh Shrotriya Chairman and Chief Executive Officer New CEO to assume duties immediately IRVINE, Calif., Aug. 16 /PRNewswire-FirstCall/ -- The Board of Directors of NeoTherapeutics, Inc. (Nasdaq: NEOT) announced today the appointment of Rajesh C. Shrotriya, M.D.
Displaying 881 - 886 of 886